Genelux CSO Yu Yong sells $1,798 of common stock
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Genelux Corp (GNLX)
Assess today's live Genelux Corp (GNLX) share price, performance and insights using our live NASDAQ: GNLX stock exchange data.
Analyse the historical data and Genelux Corp share price performance charts on this page. Our technical summary section provides analysis on Genelux share price buy/sell indicators using real-time data (or discuss the Genelux (GNLX) stock price today with other investors in the Genelux NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ GNLX share price (ISIN: US36870H1032) to enhance your trading decisions with our free investment tools and resources.
What Is the Genelux Corp Share Price Today?
The Genelux share price today is 2.800.
What Is the Stock Symbol for Genelux Corp
The stock symbol (or 'ticker') for Genelux Corp is "GNLX."
What Stock Exchange Does Genelux Corp Trade On?
Genelux Corp is listed and trades on the NASDAQ stock exchange.
Is Genelux Corp a Good Stock to Buy?
Determining whether Genelux Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Genelux Corp share price performance charts on this page. Our technical summary section provides analysis on Genelux share price buy/sell indicators using real-time data (or discuss the Genelux (GNLX) stock price today with other investors in the Genelux NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ GNLX share price (ISIN: US36870H1032) to enhance your trading decisions with our free investment tools and resources.
What Is the Genelux Corp Share Price Today?
The Genelux share price today is 2.800.
What Is the Stock Symbol for Genelux Corp
The stock symbol (or 'ticker') for Genelux Corp is "GNLX."
What Stock Exchange Does Genelux Corp Trade On?
Genelux Corp is listed and trades on the NASDAQ stock exchange.
Is Genelux Corp a Good Stock to Buy?
Determining whether Genelux Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.740
2.890
52 wk Range
2.290
8.535
GNLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.7402.890
52 wk Range
2.2908.535
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GNLX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
17.500
Upside
+525.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Genelux head of regulatory sells $1.4k in shares
- Investing.com
- Cappello, Genelux CTO, sells $2192 in GNLX stock
- Investing.com
- Genelux CSO Yu Yong sells $1,798 of common stock
- Investing.com
- Genelux head of regulatory sells $804 in stock
- Investing.com
- Form DEF 14A GENELUX CORPORATION For: 29 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.500
(+525.00% Upside)
Earnings
Latest Release
07/05/2026
EPS / Forecast
-0.20 / -0.21
Revenue / Forecast
-- / --
Compare GNLX to Peers and Sector
Metrics to compare | GNLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGNLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.7x | −2.7x | −0.5x | |
PEG Ratio | −1.10 | 0.00 | 0.00 | |
Price/Book | 5.4x | 1.8x | 2.6x | |
Price / LTM Sales | 15,543.1x | 31.7x | 3.1x | |
Upside (Analyst Target) | - | 116.0% | 55.1% | |
Fair Value Upside | Unlock | −2.6% | 7.2% | Unlock |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Genelux (NASDAQ: GNLX) Share Price Today?
The Genelux stock price today is 2.800 USD.
What Stock Exchange Does Genelux (GNLX) Trade On?
Genelux is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Genelux?
The stock symbol (also called a 'ticker') for Genelux is "GNLX."
What Is the Current Genelux Market Capitalisation?
As of today, Genelux (NASDAQ: GNLX) market cap is 124.340M USD.
What Is Genelux's (GNLX) Earnings Per Share (TTM)?
The Genelux EPS is currently -0.852 (Trailing Twelve Months).
When Is the Next Genelux Earnings Date?
Genelux's next earnings report will be released on 18/08/2026.
Is GNLX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Genelux moving averages and other technical indicators, the daily buy/sell signal for GNLX stock is Neutral.
How Many Times Has Genelux Stock Split?
Genelux has split 0 times. (See the GNLX stock split history page for full effective split date and price information.)
How Many Employees Does Genelux Have?
Genelux has 26 employees, based on their latest Companies House report.
What is the current trading status of Genelux (NASDAQ: GNLX)?
As of 20/05/2026, Genelux (GNLX) is trading at a share price of 2.800 USD, with a previous close of 2.800 USD. The stock has fluctuated within a day range of 2.740 USD to 2.890 USD, while its 52-week range spans from 2.290 USD to 8.535 USD.
What Is Genelux (GNLX) Price Target According to Analysts?
The average 12-month price target for Genelux is 17.500 USD, with a high estimate of 31 USD and a low estimate of 10 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +525.00% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.